Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGINVERA: P1101 in Polycythaemia Vera
NCT01193699Phase 2
Key facts
- Status
- Completed
- Start
- Aug 2010
- Primary completion
- Jan 2018
- Countries
- 1
- Sponsor
- AOP Health
- Modality
- Recombinant Proteins and Enzymes
- Conditions
- polycythemia vera (PV)
01
Overview
Phase 2, open-label, single-arm trial of ropeginterferon alfa-2b in polycythemia vera (PV), sponsored by AOP Health. Primary endpoint: Maximum Tolerated Dose. Started Aug 2010; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
P1101
Ropeginterferon alfa-2b (P1101) subcutaneous injection every 2 weeks.
03
Endpoints
Primary
Maximum Tolerated Dose
Secondary
Safety and Tolerability
Beyond the preview
Go deeper on NCT01193699.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01193699.